West Pharmaceutical Services INC 8-K filings

West Pharmaceutical Services announced robust second-quarter 2026 financial results, exceeding expectations with significant increases in net sales and adjusted diluted EPS, leading to raised full-year guidance.

West Pharmaceutical Services, Inc. has entered into an Amended and Restated Technology Exchange and Crosslicense Agreement and two Distributorship Agreements with Daikyo Seiko, Ltd., extending their collaboration for another 10 years.

West Pharmaceutical Services, Inc. provides an update on a material cybersecurity attack, confirming operational recovery and no expected material impact on financial guidance.

West Pharmaceutical Services disclosed a material cybersecurity incident on May 7, 2026, involving data exfiltration and system encryption, leading to temporary operational disruptions.

West Pharmaceutical Services, Inc. reported the outcomes of its 2026 Annual Meeting of Shareholders, including director elections, executive compensation approval, auditor ratification, and a shareholder proposal.

West Pharmaceutical Services announced robust first-quarter 2026 financial results, exceeding expectations and leading to an increase in full-year revenue and EPS guidance.

West Pharmaceutical Services reported robust fourth-quarter and full-year 2025 financial results, driven by double-digit organic revenue growth in High-Value Product Components, and provided optimistic 2026 financial guidance.

West Pharmaceutical Services reports strong third-quarter 2025 financial results, exceeding guidance and raising full-year revenue and EPS forecasts.

West Pharmaceutical Services announced the departure of Kimberly Banks MacKay, Senior Vice President, General Counsel, and Corporate Secretary, effective no later than December 31, 2025.

West Pharmaceutical Services, Inc. announced robust second-quarter 2025 financial results, surpassing expectations and significantly raising its full-year revenue and adjusted earnings per share guidance, driven by strong performance in high-value products and GLP-1 elastomer growth.

West Pharmaceutical Services, Inc. announced the appointment of Robert McMahon, former CFO of Agilent Technologies, as its new Senior Vice President and Chief Financial Officer, effective August 4, 2025.

West Pharmaceutical Services' shareholders approved an amendment and restatement of the 2016 Omnibus Incentive Compensation Plan to attract, retain, and motivate key personnel while aligning their interests with those of the company's shareholders.

West Pharmaceutical Services held its 2025 Annual Meeting of Shareholders, where shareholders voted on key proposals, including director elections and amendments to the Articles of Incorporation.

West Pharmaceutical Services announces the retirement of its CFO, Bernard Birkett, and the appointment of Shane Campbell as Senior Vice President, Chief Proprietary Segment Officer.

West Pharmaceutical Services reported a slight increase in net sales and a decrease in both reported and adjusted diluted EPS for Q1 2025, but raised its full-year net sales and adjusted-diluted EPS guidance.

West Pharmaceutical Services, Inc. reports the departure of Senior Vice President and Chief Commercial Officer, Cindy Reiss-Clark, effective March 7, 2025, and outlines the terms of her separation agreement.

Cindy Reiss-Clark, Senior Vice President and Chief Commercial Officer of West Pharmaceutical Services, has departed the company, effective March 7, 2025.

West Pharmaceutical Services announced positive Q4 2024 results with revenue and profit exceeding expectations, and introduced its 2025 financial guidance, projecting continued growth in key areas.

West Pharmaceutical Services has authorized a new share repurchase program for up to 550,000 shares, set to conclude by the end of 2025.

West Pharmaceutical Services has appointed Janet Haugen, former CFO of Unisys Corporation, to its Board of Directors, increasing the board size to 12 members.

West Pharmaceutical Services announced a minor decrease in third-quarter sales but increased its full-year revenue and earnings guidance, along with a dividend increase.

Silji Abraham, Senior Vice President & Chief Technology Officer of West Pharmaceutical Services, Inc., has announced his resignation, effective December 31, 2024, to pursue other interests.

West Pharmaceutical Services announced its second-quarter 2024 financial results, which were below expectations due to customer destocking, and updated its full-year 2024 financial guidance.

West Pharmaceutical Services has entered into a new credit agreement amendment, securing a $130 million term loan to refinance existing debt and senior notes.

West Pharmaceutical Services has updated the role of its Chief Financial and Operations Officer to solely Chief Financial Officer and held its 2024 Annual Meeting of Shareholders.

West Pharmaceutical Services announced a 3% decline in first-quarter net sales but raised its full-year adjusted-diluted EPS guidance.

West Pharmaceutical Services announced its fourth-quarter and full-year 2023 financial results, showing growth in net sales but a decrease in adjusted diluted EPS for the full year, and introduced its 2024 financial guidance.